Clinical trials: Fibrostenotic Crohn's Disease
Fibrostenotic Crohn's Disease
Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers
This is an open, two-part study in healthy male volunteers, aged 30-65 years. This trial aims to understand how the human body absorbs, distributes, metabolizes and eliminates ontunisertib after a single oral dose of…
- Trial name
- NCT07672574
- Testing
- Ontunisertib, [14C]ontunisertib
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Agomab Spain S.L.U.
MASH, PSC
A Microdose Trial Investigating Binding of [68Ga]Ga-DOTA-CYS-ATH001 in Healthy Subjects and Different Patient Groups.
The goal of this clinical trial is to use positron emission tomography (PET) to evaluate and compare the binding of the novel tracer [68Ga]Ga-DOTA-Cys-ATH001 in the liver and/or gastrointestinal tract between healthy volunteers…
- Conditions
- MASH, PSC, Fibrostenotic Crohn's Disease, Healthy Volunteers
- Trial name
- NCT06562361
- Testing
- [68Ga]Ga-DOTA-Cys-ATH001
- Where
- 3 sites in Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Antaros Medical
Fibrostenotic Crohn's Disease
NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease
Many patients with Crohn's disease (CD) develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals.
- Trial name
- NCT07683325
- Testing
- Ontunisertib
- Where
- 11 sites in United States, Serbia and 1 more
- Volunteers
- 320 people
- Sponsor
- Agomab Spain S.L.U.
Fibrostenotic Crohn´s Disease
A Study to Test Whether Spesolimab Helps People With Crohn's Disease Who Have Symptoms of Bowel Obstruction
This study is open to adults, between 18 and 75 years of age, who have narrowings in the small bowel (strictures) due to Crohn's disease. Strictures can lead to bowel obstruction (blockage).
- Trial name
- NCT05013385
- Testing
- Spesolimab
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Fibrostenotic Crohn's Disease
A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease
This is a Phase 1b, open-label, exploratory study designed to evaluate the pharmacodynamic effects of PALI-2108, a phosphodiesterase-4 (PDE4) inhibitor, in patients with fibrostenotic Crohn's disease (FSCD).
- Trial name
- NCT07428096
- Testing
- PALI-2108
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Palisade Bio
Fibrostenotic Crohn's Disease
STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
Many patients with Crohn's disease develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals.
- Trial name
- NCT05843578
- Testing
- AGMB-129
- Where
- 52 sites in United States, Austria and 6 more
- Volunteers
- 103 people
- Sponsor
- Agomab Spain S.L.U.
Crohn Disease, Crohn Disease and Ulcerative Colitis
Risankizumab for Fibrostenotic Crohn's Disease Treatment
This study, titled "IL-23 Inhibitor Ustekinumab for the Treatment of Fibrotic Crohn's Disease: A Prospective, Open-Label, Randomized Controlled Study," is conducted by researchers from the First Affiliated Hospital of Wenzhou…
- Trial name
- NCT07177118
- Testing
- Ustekinumab, Risankizumab
- Volunteers
- 260 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Fibrostenotic Crohn's Disease
A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants
In patients with Crohn's disease (CD), fibrosis of the gastrointestinal (GI) tract can result in stricture (stenosis) formation and obstruction of the GI tract, causing obstructive symptoms and often requiring surgical…
- Trial name
- NCT07118878
- Testing
- AGMB-129
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Agomab Spain S.L.U.
Crohn Disease, Fibrostenotic Crohn's Disease
Artificial Intelligence For Outcomes Research in Crohn's Disease: Digital Pathology Assessment of Fibrosis and Association With Patient History and Clinical Outcomes
The goal of this retrospective observational study is to learn whether artificial intelligence-based digital pathology can measure intestinal fibrosis and help identify patients with Crohn's disease who may be at greater risk of…
- Conditions
- Crohn Disease, Fibrostenotic Crohn's Disease, CD - Crohn's Disease
- Trial name
- AIFOR-CD (NCT07795476)
- Testing
- Ph-FCS(Muc) fibrosis severity Digital Pathology biomarker
- Where
- 2 sites in Spain
- Volunteers
- 100 people
- Sponsor
- PharmaNest, Inc